Syrian Arab RepublicTuberculosis profile
Population  2017 18 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.047 (0.039–0.056) 0.26 (0.21–0.31)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.02)
Incidence  (includes HIV+TB) 3.4 (2.6–4.3) 19 (14–24)
Incidence (HIV+TB only) <0.01 (<0.01–0.015) 0.05 (0.02–0.08)
Incidence (MDR/RR-TB)** 0.32 (0.19–0.48) 1.8 (1.1–2.6)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.18 (0.17–0.19) 1.3 (1.1–1.4) 1.4 (1.2–1.7)
Males 0.2 (0.19–0.21) 1.8 (1.5–2.1) 2 (1.6–2.4)
Total 0.38 (0.35–0.41) 3.1 (2.3–3.8) 3.4 (2.6–4.3)
TB case notifications, 2017  
Total cases notified 2 845
Total new and relapse 2 745
          - % tested with rapid diagnostics at time of diagnosis 5%
          - % with known HIV status <1%
          - % pulmonary 54%
          - % bacteriologically confirmed among pulmonary 72%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.01 (0.01–0.02)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 1 9%
          - on antiretroviral therapy 1 100%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  150
(100–200)
Estimated % of TB cases with MDR/RR-TB 8% (5.1–11) 24% (16–35)  
% notified tested for rifampicin resistance 27% 41% 791
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 15, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 9, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 90% 3 191
Previously treated cases, excluding relapse, registered in 2016    
HIV-positive TB cases registered in 2016 0% 1
MDR/RR-TB cases started on second-line treatment in 2015 100% 9
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
18% (17–20)
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-11-19 Data: www.who.int/tb/data